# Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

Study · id `cardio:ct-nct01230918` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01230918](<https://clinicaltrials.gov/study/NCT01230918>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01230918

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 120 participants.

## Technical summary

Registry record NCT01230918. Allocation not applicable; no masking; primary purpose diagnostic. Start 2011-05 (registry gives no type); primary completion 2017-04-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT01230918, source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01230918, source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)
- Primary completion: 2017-04-20 (actual) (ClinicalTrials.gov record NCT01230918, source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)
- Completion: 2017-04-20 (actual) (ClinicalTrials.gov record NCT01230918, source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT01230918, source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01230918-2017-04-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
- Acronym: SCAR
- Condition: Hypertrophic Cardiomyopathy
- Condition: Acute Coronary Syndrome
- Intervention (Radiation): 99mTc-NC100692
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: 317d6b6a67cb2d66d93f341d8eaf8e32c43efd5e8402d0d433cf79f80da87a85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
